Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2019 Dec 26;20(3):198–200. doi: 10.1016/j.clml.2019.12.013

Table 1.

Patients’ characteristics

Median age, y (range) 66 (44– 78)
Female, n % 8 (45%)
Median prior lines of therapy, n (range) 5 (1–11)
Prior Daratumumab exposure, n % 8 (45%)
Prior ASCT, n % 15 (83%)
Median time (years) since initial diagnosis of MM (range), y (range) 4 (1–9)

Footnote: the number above refer to all 18 patients who received treatment with SId